This company develops first-in-class and best-in-class therapeutic candidates for hard-to-treat cancers and Alzheimer’s disease. They leverage innate and adaptive immune checkpoints, including CTLA-4, CD24, and Siglec, to enhance immune response against cancer cells. Their pipeline utilizes diverse modalities such as monoclonal antibodies, bispecific antibodies, ADCs, and CAR T-cell therapies to create safer and more durable treatments.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to existing immunotherapies by exploiting innate and adaptive immune checkpoints, limiting treatment efficacy and patient outcomes. Current approaches often fail to adequately address these resistance mechanisms, particularly in hard-to-treat malignancies.
Solution
The company is developing a portfolio of novel immunotherapy products designed to overcome cancer evasion by targeting key immune checkpoints, such as CTLA-4, CD24, and Siglec. Their approach aims to enhance the body's natural immune response against cancer cells, improving the effectiveness and safety of treatments for patients with resistant or refractory tumors. By employing diverse therapeutic modalities, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapies, they seek to provide more durable and effective solutions for a wide range of cancers.
Target Audience
The primary target audience includes patients with hard-to-treat cancers that have developed resistance to existing immunotherapies, as well as oncologists and researchers seeking more effective and safer treatment options.
Features
- Gotistobart: A CTLA-4 antibody therapy being developed in partnership with BioNTech, designed to treat immunotherapy-resistant non-small cell lung cancer and other advanced tumors.
- Siglec-targeting programs: Modulating Siglec signaling to enhance cancer immunity and reduce adverse events associated with immunotherapy, ADCs, and other cancer treatments.
- CD24 platform: A cancer-specific antibody targeting CD24, which is overexpressed in a high percentage of cancers, to treat both solid and hematologic malignancies.
- Diverse therapeutic modalities: Utilizing monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and CAR T-cell therapies to target cancer cells.